Home Equities Score Pluristem Therapeutics (PSTI) stock surged in the premarket trading session; here’s why

Pluristem Therapeutics (PSTI) stock surged in the premarket trading session; here’s why

In the premarket trading session, Pluristem Therapeutics Inc. (PSTI) stock has surged by 13.94% to the price of $5.15 at the time of writing. PSTI stock closed the previous session at $4.52 gaining 1.57%. The PSTI stock volume traded today at 0.22 million shares. PSTI stock slumped by -58.26% in the past year while in the past week, the shares jumped by 4.39%. Pluristem Therapeutics Incis currently valued in the market at $144.46 million and has 31.74 million outstanding shares.

About Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. is a bio-therapeutics company that focuses on finding, designing, developing, and commercializing therapeutic products and treatments in order to cure and treat the unmet needs of certain diseases. The bio-therapeutics company along with its subsidiary Pluristem Ltd. specifically manufactures cell therapeutic products for the treatment of various ischemic, autoimmune disorders, inflammatory and hematologic conditions and disorders.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

What kind of cell-therapies does Pluristem produce?

The company produces these cell therapy products which are placental expanded (PLX) based. Pluristem also has a Phase III clinical trial of PLX-PAD cells for the treatment of critical limb ischemia (CLI) for patients that are not fit and suitable for revascularization. This treatment will also help in the recovery after surgery for hip fracture, and acute radiation syndrome (ARS). Furthermore, PLX-PAD cells can also be therapy for peripheral and cardiovascular, and orthopedic diseases.

Expansive list of commercialization agreement for clinical trials

The company has made many license and commercialization agreements in the past for conducting clinical trials and commercialization of its cell therapeutic products. This includes treatment CLI and intermittent claudication in South Korea

For evaluating the potential of PLX cell therapies in preventing and treating medical conditions that take place during outer space missions, Pluristem has collaborated with NASA’s Ames Research Center. Along with NASA, PSTI stock has also collaborated with BCRT and BCAT to expand its clinical operations and research work; a joint project was launched for treatment and therapy of inflammatory as well as respiratory complications that are formed due to COVID-19 virus– PLX cells were evaluated to check their regenerative efficacy for treatment of these complications.

Announcing the positive result of the PLX-R18 hematology program

Today, 29th April 2021, Pluristem Therapeutics has announced that the phase I study of the innovative hematology program has delivered positive results. The study uses PLX-R18 – in humans -which is the first of its kind. To recover from the incomplete hematopoietic recovery following hematopoietic cell transplantation, Pluristemhas created PLX-R18 cells which are in Phase I clinical trial. PLX-R18 are also being researched and evaluated for the treatment of ARS. PLX-R18’s efficacy and safety was tested in the dose-escalation through intramuscular injections.

Why PLX-R18 cell therapy is a deal-maker for PSTI stock?

The study found out that PLX-R18 supports the blood cell lineage’s recovery, allowing assistance in the regenerative properties of hematopoietic cells. This is an important result because the complications with patients undergoing HCT like poor graft functioning can be life-threatening. Current treatments are not that effective to satisfy blood count and patients still face recurring infections which require more blood transfusions.

The PLX-R18 is the first candidate product which is manufactured by using 3D bioreactor system and the serum-free proprietary media of Pluristem.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Why is Autolus Therapeutics plc (AUTL) stock rising today?

Shares of  Autolus Therapeutics plc (AUTL) stock were rising today on June 11, 2021, following the release of the presentation data related to obe-cel...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Related News

Vertex Pharmaceuticals Inc. (VRTX) stock plunged during after-hour. Here’s what you should know

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) stock gained by 1.5% at last close while the VRTX stock price declines during after-hour by 12.95%. Vertex is...

Bit Digital Inc. (BTBT) stock plunges during the current market trading session. What is happening?

Bit Digital Inc. (NASDAQ: BTBT) stock declined by -1.43% in the current market trading as of this writing. Bit Digital, Inc. is a Bitcoin...

Celsion Corporation (CLSN) stock gains in Pre-Market: Let’s Find out why.

Shares of Celsion Corporation (CLSN) stock were gaining in the pre-market today on June 10, 2021, following the announcement of new appointments by Celsion...

Medley Management Inc. (MDLY) stock soars during pre-market trading, given no recent update

Medley Management Inc. (NASDAQ: MDLY) stock gained by 8.96% at last close while the MDLY stock price rises by 108.90% in the pre-market trading...

Sphere 3D Corp. (ANY) stock surged during after-hour session. Why so?

Sphere 3D Corp. (NASDAQ: ANY) stock gained by 10.5% at last close while the ANY stock price soars further during the after-hour session by...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam